HWM
INO icon

Hemington Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Hemington Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-97
Closed – – 1610
2025
Q1 		$0 Hold
97
– – ﹤0.01% 1621
2024
Q4 		$0 Hold
97
– – ﹤0.01% 1656
2024
Q3 		$0 Buy
+97
New +$800 ﹤0.01% 1608

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hemington Wealth Management's INO Position: Q2 2025 in Review

Hemington Wealth Management sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 97 shares.

Hemington Wealth Management first reported a position in INO in Q3 2024 and held it in 3 quarters. The position peaked at $0 in Q1 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

  • Hemington Wealth Management reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hemington Wealth Management sold 97 Inovio Pharmaceuticals shares in Q2 2025.
  • Hemington Wealth Management first reported a position in Inovio Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Hemington Wealth Management's Inovio Pharmaceuticals position peaked at $0 in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on Hemington Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.